Daewoong대웅
003090 · KOSPI · ₩003090 · 대웅
₩15,110▲ ₩210 (1.41%)End-of-day · Oct 30, 2026 · End-of-day prices.
Filings
- Decision on Provision of Debt Guarantee to Third Party (Material Management Matter of Subsidiary)타인에대한채무보증결정(자회사의 주요경영사항)Sep 4, 2026Open on DART
- Lawsuit filed or ruled소송등의제기ㆍ신청(일정금액이상의청구)(자회사의 주요경영사항)Sep 2, 2026Open on DART
- Half-year report (Jun 2026)반기보고서 (2026.06)Aug 14, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(자회사의 주요경영사항) (펙수클루정(Fexuclue)의 적응증 추가 국내 3상 임상시험계획(IND) 승인(미란성 위식도역류질환 치료 후 유지요법))Jul 10, 2026Open on DART
- [Amendment] New Facility Investment, etc. (Major Management Matters of Subsidiary)[기재정정]신규시설투자등(자회사의 주요경영사항)Jun 30, 2026Open on DART
- Major sales or supply contract단일판매ㆍ공급계약체결(자회사의 주요경영사항)Jun 26, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(자회사의 주요경영사항) (펙수클루정(Fexuclue)의 적응증 추가 3상 임상시험계획(IND) 승인(위궤양의 치료 요법))Jun 23, 2026Open on DART
- Disclosure of Corporate Governance Report기업지배구조보고서공시Jun 1, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(자회사의 주요경영사항) (엔블로젬(Envlozem)의 국내 품목허가 신청)May 26, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(자회사의 주요경영사항) (엔블로정(Envlo) 0.3mg 멕시코 품목허가 승인)May 26, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(자회사의 주요경영사항) (비만치료용 세마글루타이드(4주 장기지속형 주사제) 기술도입 계약 체결)May 21, 2026Open on DART
- Amended: Major management matter relevant to investors[기재정정]투자판단관련주요경영사항(자회사의 주요경영사항) (mRNA 기반 Epigenetic Reprogramming of Aging (ERA) 기술이전 계약 지위 승계)May 20, 2026Open on DART
- Quarterly report (Mar 2026)분기보고서 (2026.03)May 15, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(자회사의 주요경영사항) (INV008(15PGDH 저해제) 기술도입 계약 체결)May 12, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(자회사의 주요경영사항) (mRNA 기반 Epigenetic Reprogramming of Aging (ERA) 기술이전 계약 지위 승계)May 7, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(자회사의 주요경영사항) (펙수클루정(Fexuclue)의 적응증 추가 국내 품목허가 승인(헬리코박터파일로리 제균을 위한 항생제 병용요법))Apr 30, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(자회사의 주요경영사항)Apr 10, 2026Open on DART
- Change in largest shareholder's holdings최대주주등소유주식변동신고서Mar 26, 2026Open on DART
- Annual general meeting results정기주주총회결과Mar 26, 2026Open on DART
- Audit report submitted감사보고서제출(자회사의 주요경영사항)Mar 23, 2026Open on DART
- Annual report (Dec 2025)사업보고서 (2025.12)Mar 18, 2026Open on DART
- Amended attachment: Audit report submitted[첨부정정]감사보고서제출Mar 11, 2026Open on DART
- Audit report submitted감사보고서제출(자회사의 주요경영사항)Mar 9, 2026Open on DART
- Audit report submitted감사보고서제출Mar 9, 2026Open on DART
- Change in revenue or profit of 30% or more매출액또는손익구조30%(대규모법인은15%)이상변경(자회사의 주요경영사항)Mar 9, 2026Open on DART
- Audit report submitted감사보고서제출(자회사의 주요경영사항)Mar 9, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(자회사의 주요경영사항)Mar 5, 2026Open on DART
- Reference Document for Proxy Solicitation of Voting Rights의결권대리행사권유참고서류Feb 26, 2026Open on DART
- Notice of shareholders' meeting주주총회소집공고Feb 26, 2026Open on DART
- Cash dividend decision현금ㆍ현물배당결정(자회사의 주요경영사항)Feb 25, 2026Open on DART
- Cash dividend decision현금ㆍ현물배당결정Feb 25, 2026Open on DART
- Shareholders' meeting called주주총회소집결의Feb 25, 2026Open on DART
- Sales or supply contract terminated단일판매ㆍ공급계약해지(자회사의 주요경영사항)Feb 12, 2026Open on DART
- Change in revenue or profit of 30% or more매출액또는손익구조30%(대규모법인은15%)이상변경(자회사의 주요경영사항)Feb 9, 2026Open on DART
- Change in revenue or profit of 30% or more매출액또는손익구조30%(대규모법인은15%)이상변경Feb 9, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(자회사의 주요경영사항)Jan 23, 2026Open on DART
- Treasury share sale decision주요사항보고서(자기주식처분결정)Jan 12, 2026Open on DART
- Amended: Treasury share sale decision[기재정정]주요사항보고서(자기주식처분결정)Dec 24, 2025Open on DART
- Amended: Treasury share sale decision[기재정정]주요사항보고서(자기주식처분결정)Dec 23, 2025Open on DART
- Treasury share sale decision주요사항보고서(자기주식처분결정)Dec 23, 2025Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(자회사의 주요경영사항)Dec 19, 2025Open on DART
- Determination of Shareholder Register Closure Period or Record Date주주명부폐쇄기간또는기준일설정Dec 15, 2025Open on DART
- Quarterly report (Sep 2025)분기보고서 (2025.09)Nov 14, 2025Open on DART
- Amended: Major sales or supply contract[기재정정]단일판매ㆍ공급계약체결(자회사의 주요경영사항)Nov 13, 2025Open on DART
- [Amendment] Production Suspension (Major Management Matters of Subsidiary)[기재정정]생산중단(자회사의 주요경영사항)Oct 30, 2025Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(자회사의 주요경영사항)Oct 27, 2025Open on DART
- 5%+ holding report주식등의대량보유상황보고서(약식)Oct 1, 2025Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(자회사의 주요경영사항)Sep 15, 2025Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(자회사의 주요경영사항)Sep 5, 2025Open on DART
- Half-year report (Jun 2025)반기보고서 (2025.06)Aug 14, 2025Open on DART
Titles in Korean until English translations are added.
Also known as: Daewoong / 대웅 / 003090 / KRX:003090
Source: KRX statistical information